Detalles de la búsqueda
1.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood;
141(14): 1685-1690, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608320
2.
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
Blood;
139(1): 137-142, 2022 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657156
3.
Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study.
Biol Blood Marrow Transplant;
23(9): 1455-1462, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28528711
4.
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Haematologica;
105(12): 2872-2878, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256391
5.
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.
Leukemia;
38(1): 168-180, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38049509
6.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia;
38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
7.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol;
11(2): e101-e113, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302221
8.
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Eur J Haematol;
90(4): 263-72, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23311753
9.
The MYC-Regulated RNA-Binding Proteins hnRNPC and LARP1 Are Drivers of Multiple Myeloma Cell Growth and Disease Progression and Negatively Predict Patient Survival.
Cancers (Basel);
15(23)2023 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067212
10.
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Eur J Haematol;
88(5): 406-15, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22309072
11.
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Oncoimmunology;
11(1): 2081415, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35694192
12.
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.
J Mol Med (Berl);
100(3): 463-470, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657968
13.
Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene.
Cells;
11(2)2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053409
14.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol;
9(11): e810-e821, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328040
15.
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Cancers (Basel);
13(6)2021 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33809431
16.
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Eur J Haematol;
84(4): 337-44, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20028416
17.
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Eur J Haematol;
85(2): 99-107, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20374272
18.
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Exp Cell Res;
315(14): 2471-8, 2009 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19410573
19.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Eur J Haematol;
82(6): 440-9, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19220424
20.
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Leukemia;
2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38830959